MX2021002804A - Terapias de combinacion. - Google Patents

Terapias de combinacion.

Info

Publication number
MX2021002804A
MX2021002804A MX2021002804A MX2021002804A MX2021002804A MX 2021002804 A MX2021002804 A MX 2021002804A MX 2021002804 A MX2021002804 A MX 2021002804A MX 2021002804 A MX2021002804 A MX 2021002804A MX 2021002804 A MX2021002804 A MX 2021002804A
Authority
MX
Mexico
Prior art keywords
formula
combination therapies
inhibitor
subject
methods
Prior art date
Application number
MX2021002804A
Other languages
English (en)
Inventor
James Gail Christensen
Lars Daniel Engstrom
Peter Olson
Ruth Wei Aranda
Original Assignee
Mirati Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mirati Therapeutics Inc filed Critical Mirati Therapeutics Inc
Publication of MX2021002804A publication Critical patent/MX2021002804A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a terapias de combinación para tratar cánceres KRas G12C. En particular, la presente invención se refiere a métodos para tratar el cáncer en un sujeto que lo necesita, que comprende administrar al sujeto una cantidad terapéuticamente eficaz de una combinación de un inhibidor de SHP-2 y un inhibidor de KRAS G12C de Fórmula (I), Fórmula I-A o Fórmula I-B, composiciones farmacéuticas que comprenden cantidades terapéuticamente eficaces de los inhibidores, kits que comprenden las composiciones y métodos de uso para estos.
MX2021002804A 2018-12-05 2019-12-05 Terapias de combinacion. MX2021002804A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862775628P 2018-12-05 2018-12-05
PCT/US2019/064707 WO2020118066A1 (en) 2018-12-05 2019-12-05 Combination therapies

Publications (1)

Publication Number Publication Date
MX2021002804A true MX2021002804A (es) 2021-07-15

Family

ID=70973971

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021002804A MX2021002804A (es) 2018-12-05 2019-12-05 Terapias de combinacion.

Country Status (13)

Country Link
US (1) US20220079947A1 (es)
EP (1) EP3890716A4 (es)
JP (1) JP2022509724A (es)
KR (1) KR20210113587A (es)
CN (1) CN113164418A (es)
AU (1) AU2019392683A1 (es)
CA (1) CA3112129A1 (es)
EA (1) EA202190630A1 (es)
IL (1) IL281348A (es)
MX (1) MX2021002804A (es)
SG (1) SG11202102357RA (es)
WO (1) WO2020118066A1 (es)
ZA (1) ZA202102016B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3849536A4 (en) * 2018-09-10 2022-06-29 Mirati Therapeutics, Inc. Combination therapies
JP2022500379A (ja) * 2018-09-10 2022-01-04 ミラティ セラピューティクス， インコーポレイテッド 組み合わせ療法
US20220152026A1 (en) * 2019-02-12 2022-05-19 Novartis Ag Pharmaceutical combination comprising tno155 and a krasg12c inhibitor
TWI752580B (zh) * 2019-08-07 2022-01-11 大陸商北京加科思新藥研發有限公司 Kras突變蛋白抑制劑
CN112694475A (zh) 2019-10-23 2021-04-23 苏州泽璟生物制药股份有限公司 环烷基类和杂环烷基类抑制剂及其制备方法和应用
CN112778301A (zh) * 2019-11-07 2021-05-11 苏州泽璟生物制药股份有限公司 四氢吡啶并嘧啶类抑制剂及其制备方法和应用
CN114980976A (zh) 2019-11-27 2022-08-30 锐新医药公司 共价ras抑制剂及其用途
TW202144349A (zh) * 2020-04-30 2021-12-01 大陸商上海科州藥物研發有限公司 作為ｋｒａｓ抑制劑的雜環化合物的製備及其應用方法
KR20230042600A (ko) 2020-06-18 2023-03-28 레볼루션 메디슨즈, 인크. Ras 억제제에 대한 획득된 저항성을 지연, 예방, 및 치료하는 방법
AU2021298154A1 (en) * 2020-06-25 2023-02-23 Tolremo Therapeutics Ag Combination of a CBP/p300 bromodomain inhibitor and a KRAS inhibitor for the treatment of cancer
KR20230081726A (ko) 2020-09-03 2023-06-07 레볼루션 메디슨즈, 인크. Shp2 돌연변이가 있는 악성 종양을 치료하기 위한 sos1 억제제의 용도
WO2022133345A1 (en) 2020-12-18 2022-06-23 Erasca, Inc. Tricyclic pyridones and pyrimidones
WO2022133731A1 (en) * 2020-12-22 2022-06-30 Novartis Ag Pharmaceutical combinations comprising a kras g12c inhibitor and uses of a kras g12c inhibitor and for the treatment of cancers
JP2023554471A (ja) * 2020-12-22 2023-12-27 ノバルティス アーゲー Ｋｒａｓ ｇ１２ｃ阻害剤を含む医薬組み合わせ及び癌の治療のためのｋｒａｓ ｇ１２ｃ阻害剤の使用
WO2022165142A1 (en) * 2021-01-29 2022-08-04 Mirati Therapeutics, Inc. Combination therapies
WO2022247760A1 (zh) * 2021-05-22 2022-12-01 上海科州药物研发有限公司 作为kras抑制剂的杂环化合物，及其制备和治疗用途
TW202317100A (zh) * 2021-06-23 2023-05-01 瑞士商諾華公司 包含ｋｒａｓ ｇ１２ｃ抑制劑的藥物組合及其用於治療癌症之用途
WO2023168036A1 (en) * 2022-03-04 2023-09-07 Eli Lilly And Company Method of treatment including kras g12c inhibitors and shp2 inhibitors
WO2024076672A1 (en) * 2022-10-05 2024-04-11 Amgen Inc. Heterocyclic inhibitors of kras g12c mutant proteins and uses thereof
WO2024081363A1 (en) * 2022-10-12 2024-04-18 Revolution Medicines, Inc. Composition comprising a first ras inhibitor, second ras inhibitor and a shp2 inhibitor for use in the treatment of cancer

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6613785B2 (en) 1998-07-21 2003-09-02 Smithkline Beecham Plc Use of glucose uptake enhancer for reducing post-ischemic injury of the heart
US20040043434A1 (en) 2002-06-13 2004-03-04 Gen-Sheng Feng Shp-2 tyrosine phosphatase and embryonic stem cell differentiation
AU2003291254A1 (en) 2002-11-05 2004-06-07 Mount Sinai School Of Medicine Of New York University ; Ptpn11 (shp-2) mutations and cancer
US20080058431A1 (en) 2004-03-26 2008-03-06 Gen-Sheng Feng Modulators of Shp2 Tyrosine Phosphatase and Their Use in the Treatment of Body Weight Disorders
EP1728790A1 (en) 2005-06-01 2006-12-06 Max-Delbrück-Centrum Für Molekulare Medizin Shp-2 inhibitors, pharmaceutical compositions comprising them and their use for treating phosphatase-mediated diseases
US7547760B2 (en) 2006-07-03 2009-06-16 West Virginia University Peptides and chemical compound for inhibition of SHP2 function
US9174969B2 (en) 2008-07-21 2015-11-03 University Of South Florida Indoline scaffold SHP-2 inhibitors and cancer treatment method
NL2008335A (en) 2011-04-07 2012-10-09 Asml Netherlands Bv Lithographic apparatus, device manufacturing method, and method of correcting a mask.
RS58192B1 (sr) 2012-11-21 2019-03-29 Janssen Biotech Inc Bispecifična egfr/c-met antitela
EP3094629B1 (en) 2014-01-17 2018-08-22 Novartis AG 1-(triazin-3-yl/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions thereof for inhibiting the activity of shp2
JO3517B1 (ar) 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
EP3094627B1 (en) 2014-01-17 2018-08-22 Novartis AG 1-pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and and compositions thereof for inhibiting the activity of shp2
JO3556B1 (ar) 2014-09-18 2020-07-05 Araxes Pharma Llc علاجات مدمجة لمعالجة السرطان
WO2016172583A1 (en) 2015-04-23 2016-10-27 Novartis Ag Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
US10532977B2 (en) 2015-06-01 2020-01-14 Indiana University Research And Technology Corporation Small molecule inhibitors of protein tyrosine phosphatases and uses thereof
JP6878316B2 (ja) 2015-06-19 2021-05-26 ノバルティス アーゲー Ｓｈｐ２の活性を阻害するための化合物および組成物
ES2805232T3 (es) 2015-06-19 2021-02-11 Novartis Ag Compuestos y composiciones para inhibir la actividad de SHP2
US10256121B2 (en) 2015-07-06 2019-04-09 Tokyo Electron Limited Heated stage with variable thermal emissivity method and apparatus
US9932288B2 (en) 2015-12-09 2018-04-03 West Virginia University Chemical compound for inhibition of SHP2 function and for use as an anti-cancer agent
JP7039489B2 (ja) * 2016-05-18 2022-03-22 ミラティ セラピューティクス， インコーポレイテッド Ｋｒａｓ ｇ１２ｃ阻害剤
CN112250670B (zh) 2016-06-07 2021-06-08 北京加科思新药研发有限公司 可用作shp2抑制剂的新型杂环衍生物
ES2944547T3 (es) 2017-11-15 2023-06-22 Mirati Therapeutics Inc Inhibidores de KRas G12C

Also Published As

Publication number Publication date
JP2022509724A (ja) 2022-01-24
EP3890716A1 (en) 2021-10-13
KR20210113587A (ko) 2021-09-16
IL281348A (en) 2021-04-29
WO2020118066A1 (en) 2020-06-11
ZA202102016B (en) 2022-06-29
EP3890716A4 (en) 2022-12-21
SG11202102357RA (en) 2021-04-29
CA3112129A1 (en) 2020-06-11
CN113164418A (zh) 2021-07-23
US20220079947A1 (en) 2022-03-17
EA202190630A1 (ru) 2021-10-11
AU2019392683A1 (en) 2021-04-01

Similar Documents

Publication Publication Date Title
MX2021002804A (es) Terapias de combinacion.
PH12020551244A1 (en) Pd-1/pd-l1 inhibitors
MX2021002805A (es) Terapias de combinacion.
PH12021500004A1 (en) Pd-1/pd-l1 inhibitors
MX2023005804A (es) Piridazinonas como inhibidoras de poli(adenosin difosfato-ribosa) polimerasa 7 (parp7).
MX2021014177A (es) Inhibidores de kras con la mutacion de glicina a cisteina en el codon 12 (g12c) y usos de los mismos.
MX2020011907A (es) Inhibidores de kras g12c para el tratamiento de cancer.
ZA202007007B (en) Mcl-1 inhibitors
MX2022003537A (es) Terapias de combinacion.
MX2019011431A (es) Inhibidores de proteina 1 de muerte celular programada (pd-1)/ligando 1 de muerte programada (pd-l1).
MA48772B1 (fr) Inhibiteurs de kras g12c et leurs procédés d'utilisation
MX2022005216A (es) Piridazinonas como inhibidores de poli(adp-ribosa) polimerasa 7 (parp7).
MY196836A (en) Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors
PH12020551464A1 (en) Cd73 inhibitors
PH12020552214A1 (en) Ectonucleotidase inhibitors and methods of use thereof
MX2019011506A (es) Inhibicion de cinasa 1 de punto de control (chk1) para el tratamiento de cancer.
MX2020011684A (es) Inhibicion combinada de pd-1/pd-l1, tgfbeta y dna-pk para el tratamiento del cancer.
MX2022000390A (es) Derivados macrociclicos espirociclicos como inhibidores de mcl-1.
MX2021015770A (es) Inhibidores macrociclicos de mcl-1.
MX2020011826A (es) Composiciones de combinacion que comprenden compuestos de bisfluoroalquil-1,4-benzodiazepinona y metodos de uso de las mismas.
MX2020012782A (es) Inhibidor de ccr5 para el uso en el tratamiento de cancer.
MX2020013805A (es) Derivados de piridopirimidinona para uso como inhibidores de axl.
MX2022006179A (es) Derivados macrociclicos de indol como inhibidores de mcl-1.
MX2022005400A (es) Metodos de diagnostico y terapeuticos para el tratamiento de canceres hematologicos.
MX2022001411A (es) Metodos para tratar o prevenir canceres que implican la administracion de agentes receptores anti-ccr5.